Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock during the IPO from February 9 to 13, 2024, may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2][5] - The lawsuit claims that investors suffered damages after Metagenomi announced the termination of its collaboration with Moderna, which was a key aspect of its IPO presentation [4] Group 2: Company Background - Metagenomi is described as a "genetic medicines company" that had a significant collaboration with Moderna, including a Strategic Collaboration and License Agreement established on October 29, 2021 [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4]
MGX DEADLINE MONDAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX